Skip to main content
NCBI home page
Philosophical Transactions of the Royal Society B: Biological Sciences logoLink to Philosophical Transactions of the Royal Society B: Biological Sciences
. 1999 Oct 29;354(1390):1687–1695. doi: 10.1098/rstb.1999.0512

Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis.

D H Miller 1, A J Thompson 1
PMCID: PMC1692679  PMID: 10603620

Abstract

Magnetic resonance (MR) techniques provide an objective, sensitive and quantitative assessment of the evolving pathology in multiple sclerosis. There is an increasing definition of the pathological specificity of newer techniques, and more robust correlations with clinical evolution are emerging. As the pathophysiological basis of in vivo nuclear MR signal abnormalities is further elucidated, it is likely that the importance of MR as a tool to monitor new therapies will increase.

Full Text

The Full Text of this article is available as a PDF (163.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen I. V., McKeown S. R. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci. 1979 Mar;41(1):81–91. doi: 10.1016/0022-510x(79)90142-4. [DOI] [PubMed] [Google Scholar]
  2. Andersen O., Lycke J., Tollesson P. O., Svenningsson A., Runmarker B., Linde A. S., Aström M., Gjörstrup P., Ekholm S. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Mult Scler. 1996 Jul;1(6):348–348. doi: 10.1177/135245859600100613. [DOI] [PubMed] [Google Scholar]
  3. Arnold D. L., Matthews P. M., Francis G. S., O'Connor J., Antel J. P. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol. 1992 Mar;31(3):235–241. doi: 10.1002/ana.410310302. [DOI] [PubMed] [Google Scholar]
  4. Arnold D. L., Matthews P. M., Francis G., Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med. 1990 Apr;14(1):154–159. doi: 10.1002/mrm.1910140115. [DOI] [PubMed] [Google Scholar]
  5. BROWNELL B., HUGHES J. T. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1962 Nov;25:315–320. doi: 10.1136/jnnp.25.4.315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Barkhof F., Filippi M., Miller D. H., Scheltens P., Campi A., Polman C. H., Comi G., Adèr H. J., Losseff N., Valk J. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997 Nov;120(Pt 11):2059–2069. doi: 10.1093/brain/120.11.2059. [DOI] [PubMed] [Google Scholar]
  7. Barkhof F., Filippi M., van Waesberghe J. H., Molyneux P., Rovaris M., Lycklama à Nijeholt G., Tubridy N., Miller D. H., Yousry T. A., Radue E. W. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology. 1997 Dec;49(6):1682–1688. doi: 10.1212/wnl.49.6.1682. [DOI] [PubMed] [Google Scholar]
  8. Barkhof F., Scheltens P., Frequin S. T., Nauta J. J., Tas M. W., Valk J., Hommes O. R. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol. 1992 Nov;159(5):1041–1047. doi: 10.2214/ajr.159.5.1414773. [DOI] [PubMed] [Google Scholar]
  9. Beck R. W., Cleary P. A., Trobe J. D., Kaufman D. I., Kupersmith M. J., Paty D. W., Brown C. H. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med. 1993 Dec 9;329(24):1764–1769. doi: 10.1056/NEJM199312093292403. [DOI] [PubMed] [Google Scholar]
  10. Brück W., Bitsch A., Kolenda H., Brück Y., Stiefel M., Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol. 1997 Nov;42(5):783–793. doi: 10.1002/ana.410420515. [DOI] [PubMed] [Google Scholar]
  11. Davie C. A., Barker G. J., Thompson A. J., Tofts P. S., McDonald W. I., Miller D. H. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1997 Dec;63(6):736–742. doi: 10.1136/jnnp.63.6.736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Davie C. A., Barker G. J., Webb S., Tofts P. S., Thompson A. J., Harding A. E., McDonald W. I., Miller D. H. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain. 1995 Dec;118(Pt 6):1583–1592. doi: 10.1093/brain/118.6.1583. [DOI] [PubMed] [Google Scholar]
  13. Dousset V., Armand J. P., Lacoste D., Mièze S., Letenneur L., Dartigues J. F., Caill J. M. Magnetization transfer study of HIV encephalitis and progressive multifocal leukoencephalopathy. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. AJNR Am J Neuroradiol. 1997 May;18(5):895–901. [PMC free article] [PubMed] [Google Scholar]
  14. Dousset V., Brochet B., Vital A., Gross C., Benazzouz A., Boullerne A., Bidabe A. M., Gin A. M., Caille J. M. Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer. AJNR Am J Neuroradiol. 1995 Feb;16(2):225–231. [PMC free article] [PubMed] [Google Scholar]
  15. Dousset V., Gayou A., Brochet B., Caille J. M. Early structural changes in acute MS lesions assessed by serial magnetization transfer studies. Neurology. 1998 Oct;51(4):1150–1155. doi: 10.1212/wnl.51.4.1150. [DOI] [PubMed] [Google Scholar]
  16. Dousset V., Grossman R. I., Ramer K. N., Schnall M. D., Young L. H., Gonzalez-Scarano F., Lavi E., Cohen J. A. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology. 1992 Feb;182(2):483–491. doi: 10.1148/radiology.182.2.1732968. [DOI] [PubMed] [Google Scholar]
  17. Durelli L., Bongioanni M. R., Cavallo R., Ferrero B., Ferri R., Ferrio M. F., Bradac G. B., Riva A., Vai S., Geuna M. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology. 1994 Mar;44(3 Pt 1):406–413. doi: 10.1212/wnl.44.3_part_1.406. [DOI] [PubMed] [Google Scholar]
  18. Edan G., Miller D., Clanet M., Confavreux C., Lyon-Caen O., Lubetzki C., Brochet B., Berry I., Rolland Y., Froment J. C. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 1997 Feb;62(2):112–118. doi: 10.1136/jnnp.62.2.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Evans A. C., Frank J. A., Antel J., Miller D. H. The role of MRI in clinical trials of multiple sclerosis: comparison of image processing techniques. Ann Neurol. 1997 Jan;41(1):125–132. doi: 10.1002/ana.410410123. [DOI] [PubMed] [Google Scholar]
  20. Ferguson B., Matyszak M. K., Esiri M. M., Perry V. H. Axonal damage in acute multiple sclerosis lesions. Brain. 1997 Mar;120(Pt 3):393–399. doi: 10.1093/brain/120.3.393. [DOI] [PubMed] [Google Scholar]
  21. Filippi M., Campi A., Mammi S., Martinelli V., Locatelli T., Scotti G., Amadio S., Canal N., Comi G. Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 1995 Jan;58(1):31–37. doi: 10.1136/jnnp.58.1.31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Filippi M., Campi A., Martinelli V., Colombo B., Yousry T., Canal N., Scotti G., Comi G. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 1995 Nov;59(5):540–544. doi: 10.1136/jnnp.59.5.540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Filippi M., Horsfield M. A., Adèr H. J., Barkhof F., Bruzzi P., Evans A., Frank J. A., Grossman R. I., McFarland H. F., Molyneux P. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol. 1998 Apr;43(4):499–506. doi: 10.1002/ana.410430414. [DOI] [PubMed] [Google Scholar]
  24. Filippi M., Horsfield M. A., Bressi S., Martinelli V., Baratti C., Reganati P., Campi A., Miller D. H., Comi G. Intra- and inter-observer agreement of brain MRI lesion volume measurements in multiple sclerosis. A comparison of techniques. Brain. 1995 Dec;118(Pt 6):1593–1600. doi: 10.1093/brain/118.6.1593. [DOI] [PubMed] [Google Scholar]
  25. Filippi M., Horsfield M. A., Campi A., Mammi S., Pereira C., Comi G. Resolution-dependent estimates of lesion volumes in magnetic resonance imaging studies of the brain in multiple sclerosis. Ann Neurol. 1995 Nov;38(5):749–754. doi: 10.1002/ana.410380509. [DOI] [PubMed] [Google Scholar]
  26. Filippi M., Horsfield M. A., Morrissey S. P., MacManus D. G., Rudge P., McDonald W. I., Miller D. H. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology. 1994 Apr;44(4):635–641. doi: 10.1212/wnl.44.4.635. [DOI] [PubMed] [Google Scholar]
  27. Filippi M., Rovaris M., Capra R., Gasperini C., Yousry T. A., Sormani M. P., Prandini F., Horsfield M. A., Martinelli V., Bastianello S. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain. 1998 Oct;121(Pt 10):2011–2020. doi: 10.1093/brain/121.10.2011. [DOI] [PubMed] [Google Scholar]
  28. Gass A., Barker G. J., Kidd D., Thorpe J. W., MacManus D., Brennan A., Tofts P. S., Thompson A. J., McDonald W. I., Miller D. H. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol. 1994 Jul;36(1):62–67. doi: 10.1002/ana.410360113. [DOI] [PubMed] [Google Scholar]
  29. Gawne-Cain M. L., O'Riordan J. I., Coles A., Newell B., Thompson A. J., Miller D. H. MRI lesion volume measurement in multiple sclerosis and its correlation with disability: a comparison of fast fluid attenuated inversion recovery (fFLAIR) and spin echo sequences. J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):197–203. doi: 10.1136/jnnp.64.2.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Gawne-Cain M. L., O'Riordan J. I., Thompson A. J., Moseley I. F., Miller D. H. Multiple sclerosis lesion detection in the brain: a comparison of fast fluid-attenuated inversion recovery and conventional T2-weighted dual spin echo. Neurology. 1997 Aug;49(2):364–370. doi: 10.1212/wnl.49.2.364. [DOI] [PubMed] [Google Scholar]
  31. Giovannoni G., Lai M., Thorpe J., Kidd D., Chamoun V., Thompson A. J., Miller D. H., Feldmann M., Thompson E. J. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology. 1997 Jun;48(6):1557–1565. doi: 10.1212/wnl.48.6.1557. [DOI] [PubMed] [Google Scholar]
  32. Grimaud J., Lai M., Thorpe J., Adeleine P., Wang L., Barker G. J., Plummer D. L., Tofts P. S., McDonald W. I., Miller D. H. Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques. Magn Reson Imaging. 1996;14(5):495–505. doi: 10.1016/0730-725x(96)00018-5. [DOI] [PubMed] [Google Scholar]
  33. Grossman R. I., Gonzalez-Scarano F., Atlas S. W., Galetta S., Silberberg D. H. Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology. 1986 Dec;161(3):721–725. doi: 10.1148/radiology.161.3.3786722. [DOI] [PubMed] [Google Scholar]
  34. Harris J. O., Frank J. A., Patronas N., McFarlin D. E., McFarland H. F. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol. 1991 May;29(5):548–555. doi: 10.1002/ana.410290515. [DOI] [PubMed] [Google Scholar]
  35. Hawkins C. P., Munro P. M., MacKenzie F., Kesselring J., Tofts P. S., du Boulay E. P., Landon D. N., McDonald W. I. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain. 1990 Apr;113(Pt 2):365–378. doi: 10.1093/brain/113.2.365. [DOI] [PubMed] [Google Scholar]
  36. Jacobs L. D., Cookfair D. L., Rudick R. A., Herndon R. M., Richert J. R., Salazar A. M., Fischer J. S., Goodkin D. E., Granger C. V., Simon J. H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol. 1996 Mar;39(3):285–294. doi: 10.1002/ana.410390304. [DOI] [PubMed] [Google Scholar]
  37. Kapoor R., Miller D. H., Jones S. J., Plant G. T., Brusa A., Gass A., Hawkins C. P., Page R., Wood N. W., Compston D. A. Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology. 1998 Jan;50(1):230–237. doi: 10.1212/wnl.50.1.230. [DOI] [PubMed] [Google Scholar]
  38. Karussis D. M., Meiner Z., Lehmann D., Gomori J. M., Schwarz A., Linde A., Abramsky O. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology. 1996 Aug;47(2):341–346. doi: 10.1212/wnl.47.2.341. [DOI] [PubMed] [Google Scholar]
  39. Katz D., Taubenberger J. K., Cannella B., McFarlin D. E., Raine C. S., McFarland H. F. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol. 1993 Nov;34(5):661–669. doi: 10.1002/ana.410340507. [DOI] [PubMed] [Google Scholar]
  40. Kidd D., Barkhof F., McConnell R., Algra P. R., Allen I. V., Revesz T. Cortical lesions in multiple sclerosis. Brain. 1999 Jan;122(Pt 1):17–26. doi: 10.1093/brain/122.1.17. [DOI] [PubMed] [Google Scholar]
  41. Kidd D., Thorpe J. W., Kendall B. E., Barker G. J., Miller D. H., McDonald W. I., Thompson A. J. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996 Jan;60(1):15–19. doi: 10.1136/jnnp.60.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Kidd D., Thorpe J. W., Thompson A. J., Kendall B. E., Moseley I. F., MacManus D. G., McDonald W. I., Miller D. H. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology. 1993 Dec;43(12):2632–2637. doi: 10.1212/wnl.43.12.2632. [DOI] [PubMed] [Google Scholar]
  43. Koopmans R. A., Li D. K., Grochowski E., Cutler P. J., Paty D. W. Benign versus chronic progressive multiple sclerosis: magnetic resonance imaging features. Ann Neurol. 1989 Jan;25(1):74–81. doi: 10.1002/ana.410250112. [DOI] [PubMed] [Google Scholar]
  44. Lai H. M., Davie C. A., Gass A., Barker G. J., Webb S., Tofts P. S., Thompson A. J., McDonald W. I., Miller D. H. Serial magnetisation transfer ratios in gadolinium-enhancing lesions in multiple sclerosis. J Neurol. 1997 May;244(5):308–311. doi: 10.1007/s004150050092. [DOI] [PubMed] [Google Scholar]
  45. Lai M., Hodgson T., Gawne-Cain M., Webb S., MacManus D., McDonald W. I., Thompson A. J., Miller D. H. A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996 Mar;60(3):339–341. doi: 10.1136/jnnp.60.3.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Losseff N. A., Kingsley D. P., McDonald W. I., Miller D. H., Thompson A. J. Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis. Mult Scler. 1996 Feb;1(4):218–222. [PubMed] [Google Scholar]
  47. Losseff N. A., Wang L., Lai H. M., Yoo D. S., Gawne-Cain M. L., McDonald W. I., Miller D. H., Thompson A. J. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain. 1996 Dec;119(Pt 6):2009–2019. doi: 10.1093/brain/119.6.2009. [DOI] [PubMed] [Google Scholar]
  48. Losseff N. A., Webb S. L., O'Riordan J. I., Page R., Wang L., Barker G. J., Tofts P. S., McDonald W. I., Miller D. H., Thompson A. J. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain. 1996 Jun;119(Pt 3):701–708. doi: 10.1093/brain/119.3.701. [DOI] [PubMed] [Google Scholar]
  49. MacKay A., Whittall K., Adler J., Li D., Paty D., Graeb D. In vivo visualization of myelin water in brain by magnetic resonance. Magn Reson Med. 1994 Jun;31(6):673–677. doi: 10.1002/mrm.1910310614. [DOI] [PubMed] [Google Scholar]
  50. Mancardi G. L., Sardanelli F., Parodi R. C., Melani E., Capello E., Inglese M., Ferrari A., Sormani M. P., Ottonello C., Levrero F. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology. 1998 Apr;50(4):1127–1133. doi: 10.1212/wnl.50.4.1127. [DOI] [PubMed] [Google Scholar]
  51. Matthews P. M., Pioro E., Narayanan S., De Stefano N., Fu L., Francis G., Antel J., Wolfson C., Arnold D. L. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain. 1996 Jun;119(Pt 3):715–722. doi: 10.1093/brain/119.3.715. [DOI] [PubMed] [Google Scholar]
  52. McFarland H. F., Frank J. A., Albert P. S., Smith M. E., Martin R., Harris J. O., Patronas N., Maloni H., McFarlin D. E. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol. 1992 Dec;32(6):758–766. doi: 10.1002/ana.410320609. [DOI] [PubMed] [Google Scholar]
  53. Miller D. H., Albert P. S., Barkhof F., Francis G., Frank J. A., Hodgkinson S., Lublin F. D., Paty D. W., Reingold S. C., Simon J. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol. 1996 Jan;39(1):6–16. doi: 10.1002/ana.410390104. [DOI] [PubMed] [Google Scholar]
  54. Miller D. H., Barkhof F., Nauta J. J. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain. 1993 Oct;116(Pt 5):1077–1094. doi: 10.1093/brain/116.5.1077. [DOI] [PubMed] [Google Scholar]
  55. Miller D. H., Johnson G., Tofts P. S., MacManus D., McDonald W. I. Precise relaxation time measurements of normal-appearing white matter in inflammatory central nervous system disease. Magn Reson Med. 1989 Sep;11(3):331–336. doi: 10.1002/mrm.1910110307. [DOI] [PubMed] [Google Scholar]
  56. Miller D. H., Newton M. R., van der Poel J. C., du Boulay E. P., Halliday A. M., Kendall B. E., Johnson G., MacManus D. G., Moseley I. F., McDonald W. I. Magnetic resonance imaging of the optic nerve in optic neuritis. Neurology. 1988 Feb;38(2):175–179. doi: 10.1212/wnl.38.2.175. [DOI] [PubMed] [Google Scholar]
  57. Moll C., Mourre C., Lazdunski M., Ulrich J. Increase of sodium channels in demyelinated lesions of multiple sclerosis. Brain Res. 1991 Aug 16;556(2):311–316. doi: 10.1016/0006-8993(91)90321-l. [DOI] [PubMed] [Google Scholar]
  58. Molyneux P. D., Tofts P. S., Fletcher A., Gunn B., Robinson P., Gallagher H., Moseley I. F., Barker G. J., Miller D. H. Precision and reliability for measurement of change in MRI lesion volume in multiple sclerosis: a comparison of two computer assisted techniques. J Neurol Neurosurg Psychiatry. 1998 Jul;65(1):42–47. doi: 10.1136/jnnp.65.1.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Molyneux P. D., Tubridy N., Parker G. J., Barker G. J., MacManus D. G., Tofts P. S., Moseley I. F., Miller D. H. The effect of section thickness on MR lesion detection and quantification in multiple sclerosis. AJNR Am J Neuroradiol. 1998 Oct;19(9):1715–1720. [PMC free article] [PubMed] [Google Scholar]
  60. Moreau T., Thorpe J., Miller D., Moseley I., Hale G., Waldmann H., Clayton D., Wing M., Scolding N., Compston A. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet. 1994 Jul 30;344(8918):298–301. doi: 10.1016/s0140-6736(94)91339-0. [DOI] [PubMed] [Google Scholar]
  61. Morrissey S. P., Miller D. H., Kendall B. E., Kingsley D. P., Kelly M. A., Francis D. A., MacManus D. G., McDonald W. I. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain. 1993 Feb;116(Pt 1):135–146. doi: 10.1093/brain/116.1.135. [DOI] [PubMed] [Google Scholar]
  62. Nauta J. J., Thompson A. J., Barkhof F., Miller D. H. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci. 1994 Mar;122(1):6–14. doi: 10.1016/0022-510x(94)90045-0. [DOI] [PubMed] [Google Scholar]
  63. Nesbit G. M., Forbes G. S., Scheithauer B. W., Okazaki H., Rodriguez M. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology. 1991 Aug;180(2):467–474. doi: 10.1148/radiology.180.2.2068314. [DOI] [PubMed] [Google Scholar]
  64. O'Riordan J. I., Losseff N. A., Phatouros C., Thompson A. J., Moseley I. F., MacManus D. G., McDonald W. I., Miller D. H. Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of demyelination. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):353–357. doi: 10.1136/jnnp.64.3.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. O'Riordan J. I., Thompson A. J., Kingsley D. P., MacManus D. G., Kendall B. E., Rudge P., McDonald W. I., Miller D. H. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain. 1998 Mar;121(Pt 3):495–503. doi: 10.1093/brain/121.3.495. [DOI] [PubMed] [Google Scholar]
  66. Ormerod I. E., Miller D. H., McDonald W. I., du Boulay E. P., Rudge P., Kendall B. E., Moseley I. F., Johnson G., Tofts P. S., Halliday A. M. The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain. 1987 Dec;110(Pt 6):1579–1616. doi: 10.1093/brain/110.6.1579. [DOI] [PubMed] [Google Scholar]
  67. Rao S. M., Leo G. J., Haughton V. M., St Aubin-Faubert P., Bernardin L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology. 1989 Feb;39(2 Pt 1):161–166. doi: 10.1212/wnl.39.2.161. [DOI] [PubMed] [Google Scholar]
  68. Ron M. A., Callanan M. M., Warrington E. K. Cognitive abnormalities in multiple sclerosis: a psychometric and MRI study. Psychol Med. 1991 Feb;21(1):59–68. doi: 10.1017/s0033291700014653. [DOI] [PubMed] [Google Scholar]
  69. Rudick R., Antel J., Confavreux C., Cutter G., Ellison G., Fischer J., Lublin F., Miller A., Petkau J., Rao S. Clinical outcomes assessment in multiple sclerosis. Ann Neurol. 1996 Sep;40(3):469–479. doi: 10.1002/ana.410400321. [DOI] [PubMed] [Google Scholar]
  70. Silver N. C., Barker G. J., MacManus D. G., Miller D. H., Thorpe J. W., Howard R. S. Decreased magnetisation transfer ratio due to demyelination: a case of central pontine myelinolysis. J Neurol Neurosurg Psychiatry. 1996 Aug;61(2):208–209. doi: 10.1136/jnnp.61.2.208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Silver N. C., Good C. D., Barker G. J., MacManus D. G., Thompson A. J., Moseley I. F., McDonald W. I., Miller D. H. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain. 1997 Jul;120(Pt 7):1149–1161. doi: 10.1093/brain/120.7.1149. [DOI] [PubMed] [Google Scholar]
  72. Smith M. E., Stone L. A., Albert P. S., Frank J. A., Martin R., Armstrong M., Maloni H., McFarlin D. E., McFarland H. F. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol. 1993 May;33(5):480–489. doi: 10.1002/ana.410330511. [DOI] [PubMed] [Google Scholar]
  73. Sorensen P. S., Wanscher B., Jensen C. V., Schreiber K., Blinkenberg M., Ravnborg M., Kirsmeier H., Larsen V. A., Lee M. L. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology. 1998 May;50(5):1273–1281. doi: 10.1212/wnl.50.5.1273. [DOI] [PubMed] [Google Scholar]
  74. Stevenson V. L., Leary S. M., Losseff N. A., Parker G. J., Barker G. J., Husmani Y., Miller D. H., Thompson A. J. Spinal cord atrophy and disability in MS: a longitudinal study. Neurology. 1998 Jul;51(1):234–238. doi: 10.1212/wnl.51.1.234. [DOI] [PubMed] [Google Scholar]
  75. Stone L. A., Frank J. A., Albert P. S., Bash C., Smith M. E., Maloni H., McFarland H. F. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol. 1995 May;37(5):611–619. doi: 10.1002/ana.410370511. [DOI] [PubMed] [Google Scholar]
  76. Söderström M., Lindqvist M., Hillert J., Käll T. B., Link H. Optic neuritis: findings on MRI, CSF examination and HLA class II typing in 60 patients and results of a short-term follow-up. J Neurol. 1994 May;241(6):391–397. doi: 10.1007/BF02033357. [DOI] [PubMed] [Google Scholar]
  77. Thompson A. J., Hobart J. C. Multiple sclerosis: assessment of disability and disability scales. J Neurol. 1998 Apr;245(4):189–196. doi: 10.1007/s004150050204. [DOI] [PubMed] [Google Scholar]
  78. Thompson A. J., Kermode A. G., MacManus D. G., Kendall B. E., Kingsley D. P., Moseley I. F., McDonald W. I. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ. 1990 Mar 10;300(6725):631–634. doi: 10.1136/bmj.300.6725.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Thompson A. J., Kermode A. G., Wicks D., MacManus D. G., Kendall B. E., Kingsley D. P., McDonald W. I. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol. 1991 Jan;29(1):53–62. doi: 10.1002/ana.410290111. [DOI] [PubMed] [Google Scholar]
  80. Thompson A. J., Miller D., Youl B., MacManus D., Moore S., Kingsley D., Kendall B., Feinstein A., McDonald W. I. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology. 1992 Jan;42(1):60–63. doi: 10.1212/wnl.42.1.60. [DOI] [PubMed] [Google Scholar]
  81. Thompson A. J., Polman C. H., Miller D. H., McDonald W. I., Brochet B., Filippi M Montalban X., De Sá J. Primary progressive multiple sclerosis. Brain. 1997 Jun;120(Pt 6):1085–1096. doi: 10.1093/brain/120.6.1085. [DOI] [PubMed] [Google Scholar]
  82. Thorpe J. W., Barker G. J., Jones S. J., Moseley I., Losseff N., MacManus D. G., Webb S., Mortimer C., Plummer D. L., Tofts P. S. Magnetisation transfer ratios and transverse magnetisation decay curves in optic neuritis: correlation with clinical findings and electrophysiology. J Neurol Neurosurg Psychiatry. 1995 Nov;59(5):487–492. doi: 10.1136/jnnp.59.5.487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Thorpe J. W., Kidd D., Moseley I. F., Kenndall B. E., Thompson A. J., MacManus D. G., McDonald W. I., Miller D. H. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology. 1996 Feb;46(2):373–378. doi: 10.1212/wnl.46.2.373. [DOI] [PubMed] [Google Scholar]
  84. Tofts P. S., Barker G. J., Filippi M., Gawne-Cain M., Lai M. An oblique cylinder contrast-adjusted (OCCA) phantom to measure the accuracy of MRI brain lesion volume estimation schemes in multiple sclerosis. Magn Reson Imaging. 1997;15(2):183–192. doi: 10.1016/s0730-725x(96)00339-6. [DOI] [PubMed] [Google Scholar]
  85. Trapp B. D., Peterson J., Ransohoff R. M., Rudick R., Mörk S., Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 Jan 29;338(5):278–285. doi: 10.1056/NEJM199801293380502. [DOI] [PubMed] [Google Scholar]
  86. Truyen L., van Waesberghe J. H., van Walderveen M. A., van Oosten B. W., Polman C. H., Hommes O. R., Adèr H. J., Barkhof F. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology. 1996 Dec;47(6):1469–1476. doi: 10.1212/wnl.47.6.1469. [DOI] [PubMed] [Google Scholar]
  87. Tubridy N., Ader H. J., Barkhof F., Thompson A. J., Miller D. H. Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups. J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):50–55. doi: 10.1136/jnnp.64.1.50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Tubridy N., Behan P. O., Capildeo R., Chaudhuri A., Forbes R., Hawkins C. P., Hughes R. A., Palace J., Sharrack B., Swingler R. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology. 1999 Aug 11;53(3):466–472. doi: 10.1212/wnl.53.3.466. [DOI] [PubMed] [Google Scholar]
  89. Tubridy N., Coles A. J., Molyneux P., Compston D. A., Barkhof F., Thompson A. J., McDonald W. I., Miller D. H. Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features. Brain. 1998 Feb;121(Pt 2):225–231. doi: 10.1093/brain/121.2.225. [DOI] [PubMed] [Google Scholar]
  90. Udupa J. K., Wei L., Samarasekera S., Miki Y., van Buchem M. A., Grossman R. I. Multiple sclerosis lesion quantification using fuzzy-connectedness principles. IEEE Trans Med Imaging. 1997 Oct;16(5):598–609. doi: 10.1109/42.640750. [DOI] [PubMed] [Google Scholar]
  91. Youl B. D., Turano G., Miller D. H., Towell A. D., MacManus D. G., Moore S. G., Jones S. J., Barrett G., Kendall B. E., Moseley I. F. The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. Brain. 1991 Dec;114(Pt 6):2437–2450. doi: 10.1093/brain/114.6.2437. [DOI] [PubMed] [Google Scholar]

Articles from Philosophical Transactions of the Royal Society B: Biological Sciences are provided here courtesy of The Royal Society

RESOURCES